Abstract
By the end of 2000, 11 monoclonal antibody-based therapeutic agents had gained regulatory approval within the European Union. Approximately 59 such products are currently undergoing evaluation, ensuring that the number of approved products will increase substantially during the next few years.
| Original language | English |
|---|---|
| Pages (from-to) | 70+72+74+76 |
| Journal | Pharmaceutical Technology Europe |
| Volume | 13 |
| Issue number | 3 |
| Publication status | Published - 2001 |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Fingerprint
Dive into the research topics of 'Monoclonal antibody-based therapeutics'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver